Loading organizations...
Key people at Haisco Pharmaceutical Group.
Haisco Pharmaceutical Group is a publicly listed pharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative and generic drugs with high technical barriers, with operational headquarters in Chengdu, China. The company employs approximately 5,448 individuals and reported an annual revenue of $478.5 million. Its therapeutic focus encompasses critical areas including anesthesia and pain management, respiratory diseases, chronic illnesses, oncology, and autoimmune disorders. Notable leadership includes Chairman Junmin Wang and Director and General Manager Pangke Yan, with Xiu Lian Fan also cited as President, CEO, and Founder in some reports. Haisco has consistently earned recognition as a "China Innovative Pharmaceutical Enterprise" and a Top 100 Pharmaceutical Commercial and Manufacturing Enterprise, with its long-acting antidiabetic drug HSK7653 securing a high-value patent award in 2023. The organization was founded in 2000.
Key people at Haisco Pharmaceutical Group.
Haisco Pharmaceutical Group has 2 tracked investments across 2 companies. The latest tracked deal is $8.0M Series B in Laminate Medical in February 2017.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 1, 2017 | Laminate Medical | $8.0M Series B | — | Adjacent, Bessemer Venture Partners, Blumberg Capital, Correlation Ventures, Earth And Beyond Ventures, Forerunner Ventures, Hanaco Ventures, Lerer Hippeau, Mouro Capital, MS&AD Ventures, RED SEA Ventures, Tamar Technology Ventures, TAU Ventures, Team8, Union Square Ventures, Daniel Shinar, Oliver Jung, Shane Neman, Yuval Shahar |
| Feb 11, 2016 | Regentis Biomaterials | $15.0M Series D | Haisco Pharmaceutical Group | Generali, Medica Venture Partners, SCP Vitalife Partners, Technion Innovation Opportunities Fund, Technion Research And Development Foundation |
